Coated Pills Or Tablets Patents (Class 424/474)
  • Patent number: 11026886
    Abstract: Disclosed is a dry powder oral formulation that includes an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation. Also disclosed are an excipient composition in absence of an API and methods of making and using the formulations and compositions. Also disclosed is a chewable, swallowable, and/or orally disintegrating tablet comprising an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: June 8, 2021
    Assignee: Marenda Pharmaceuticals LLC
    Inventors: Andrew Favara, Marc Karetny
  • Patent number: 10987324
    Abstract: Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose. The pharmaceutical compositions comprise a drug selected from the group consisting of brivaracetam, divalproex, lacosamide, levetiracetam, oxcarbazepine, vigabatrin, and pharmaceutically acceptable salts of any of the foregoing, and at least one excipient. At least one of said at least one excipients modifies the release of said drug to provide an extended release form. The pharmaceutical composition have pharmacokinetic properties recited in the claims.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: April 27, 2021
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Jack Nguyen, David Chernoff, Sangita Ghosh, Gregory T. Went, Timothy J. Fultz
  • Patent number: 10973783
    Abstract: Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose. The pharmaceutical compositions comprise a drug selected from the group consisting of brivaracetam, divalproex, lacosamide, levetiracetam, oxcarbazepine, vigabatrin, and pharmaceutically acceptable salts of any of the foregoing, and at least one excipient. At least one of said at least one excipients modifies the release of said drug to provide an extended release form. The pharmaceutical composition have pharmacokinetic properties recited in the claims.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: April 13, 2021
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Jack Nguyen, David Chernoff, Sangita Ghosh, Gregory T. Went, Timothy J. Fultz
  • Patent number: 10933076
    Abstract: A therapeutic combination of drugs for the treatment of a liver cancer includes a crocin, or a pharmaceutically acceptable pro-drug thereof, and sorafenib. A method of treating, suppressing, or reducing the severity of a liver cancer in a subject, involves administering to the subject a first amount of sorafenib, and administering to the subject a second amount of a crocin or a pharmaceutically acceptable pro-drug thereof.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: March 2, 2021
    Assignee: UNITED ARAB EMIRATES UNIVERSITY
    Inventors: Amr Amin, Basma Awad
  • Patent number: 10933143
    Abstract: An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: March 2, 2021
    Assignee: TRIS PHARMA, INC
    Inventors: Ketan Mehta, Yu-Hsing Tu
  • Patent number: 10919898
    Abstract: The present invention relates to compound III and its use for treatment and/or prevention of diseases of the schizophrenia spectrum and other psychotic disorders, first episodes of these diseases such as first episode of psychosis (FEP), relapses of these diseases such as reduction of relapse in patients with schizophrenia (REX). The invention also relates to polymorphs of compound III, and pharmaceutical compositions comprising compound III and/or its polymorphs.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: February 16, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Michael Steven Sand, Holger Rosenbrock, Riccardo Giovannini, Masashi Adachi, Bodo Betzemeier, Tobias Brodmann, Takayuki Kamata, Yohei Kawabata, Masanori Ito, Daniel Marckart, Manabu Nakatani, Ulrike Werthmann
  • Patent number: 10912796
    Abstract: A nutritional composition comprises (a) one to a plurality of physiologically acceptable calcium salts and/or chelates and (b) one or more phosphorus-containing components, such as phosphate salts, and/or phosphorus-rescuing components, such as phytase. The composition is useful for phosphorus-sparing calcium supplementation of the diet of a human subject, and for treatment of a low bone density condition in a human subject in need thereof.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 9, 2021
    Assignee: Albion Laboratories, Inc.
    Inventor: Jonathan David Bortz
  • Patent number: 10874618
    Abstract: The invention relates to a new fixed dose combination of benazepril with pimobendan.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: December 29, 2020
    Assignee: Elanco Tiergesundheit AG
    Inventors: Jernej Grmas, Zdenka Jerala-Strukelj, Sebastjan Reven
  • Patent number: 10849953
    Abstract: A food supplement to reduce symptoms of Parkinson's disease is disclosed. The food supplements contains a mixture of garlic, almond, peanut, tomato, grape, clove, black eye pea turmeric, tea and velvet bean.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: December 1, 2020
    Inventors: Muhammad Iqbal Choudhary, Atta-Ur Rahman, Atia-Tul Wahab, Humaira Zafar
  • Patent number: 10851129
    Abstract: A composition, and a crocins active site extracted from Gardenia jasminoides Ellis, mainly comprising the following ingredients: crocetin di-?-D-gentiobioside, crocetin-?-D-glucopyranosyl-?-D-gentiobioside, crocetin di-?-D-glucopyranoside, 13Z-crocetin di-?-D-gentiobioside, neocrocin B, crocetin mono-?-D-gentiobioside, 13Z-crocetin-8-O-?-D-gentiobioside, 13Z-crocetin-8?-O-?-D-gentiobioside, and crocetin mono-?-D-glucopyranoside. Pharmacological experiment results show that the crocins active site can effectively improve learning and memory injuries in mice induced by scopolamine and amyloid ? protein.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: December 1, 2020
    Assignee: Jinan University
    Inventors: Xinsheng Yao, Dan Zhang, Yang Yu, Xiuqi Bao, Yang Ni, Caixia Zang
  • Patent number: 10842805
    Abstract: The invention relates to unique compositions containing enriched and purified natural crocin and/or crocetin for prevention and/or treatment of cancers and other conditions and diseases. Compositions comprise mainly enriched or purified natural crocin or crocetin or combination of both and possible other active phytochemicals. A composition is used as functional food, drink, dietary supplement, or therapeutic dosage to a human orally or through other appropriate way (parenteral, percutaneous, rectal, mucosal, intranasal or topical administration). A method of natural crocin and crocetin enriching and purification is revealed.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: November 24, 2020
    Inventor: Song Gao
  • Patent number: 10835470
    Abstract: The present invention relates to a cosmetic composition comprising a compound represented by Formula 1 below as an active ingredient. in the above Formula 1, R1 is -glc(2-1)glc, R2 is -glc, or R1 is -glc, R2 is -glc(6-1)ara(pyr).
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: November 17, 2020
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Gi Baeg Nam, Dong Hyun Kim, Yong Deog Hong, Cheng Yi Zhang, Jun Seong Park
  • Patent number: 10786507
    Abstract: Provided in the present invention is a pharmaceutical composition containing a JAK kinase inhibitor or a pharmaceutically acceptable salt thereof. In particular, provided in the present invention is a pharmaceutical composition containing (3aR, 5s, 6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo [2,3-d] pyrimidin-4-yl) amino) hexahydrocyclopenta [c] pyrrol-2 (1H)-carboxamide, or a pharmaceutically acceptable salt thereof, and cellulose ether. The pharmaceutical composition of the present invention is characterized by a rapid dissolution rate and good stability.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: September 29, 2020
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Yun Lu, Hao Chen, Xiaochen Pan
  • Patent number: 10758580
    Abstract: The present disclosure discloses a natural pharmaceutical composition for treating osteoporotic fracture and/or osteoarthritis and an application thereof. The composition is composed of 73.3 wt %-98.3 wt % of sea buckthorn pulp oil and 1.7 wt %-26.7 wt % of panax notoginseng saponins. The composition can be further used for preventing and treating ostealgia diseases.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: September 1, 2020
    Assignee: SHAANXI TIANKUI BIOMEDICINE TECHNOLOGY LIMITED COMPANY
    Inventors: Xiazhen Wei, Lanlan Song, Shaohua Han
  • Patent number: 10736855
    Abstract: A composition suitable for forming a viscous suspension upon admixing with an aqueous medium, methods for its production and use thereof are provided. The composition includes a plurality of units, each unit having a core containing a proton pump inhibitor and an outer coating containing a gel-forming agent.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: August 11, 2020
    Assignee: DEXCEL PHARMA TECHNOLOGIES LTD.
    Inventors: Tomer Gold, Irit Ventura
  • Patent number: 10668163
    Abstract: An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: June 2, 2020
    Assignee: Tris Pharma, Inc.
    Inventors: Ketan Mehta, Yu-Hsing Tu
  • Patent number: 10624847
    Abstract: The invention provides decomposing apparatus which comprises a first sub-component and a first micro device comprising a decomposable material, wherein the sub-component comprises a drug, a medical kit, a micro-disease detection system, or an auto-navigation system. Also within the invention are methods for fabricating such apparatus.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: April 21, 2020
    Assignee: AnPac BioMedical Science Co., Ltd.
    Inventors: Chris C Yu, Xuedong Du
  • Patent number: 10603285
    Abstract: An object of the present invention is to provide [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid monobenzenesulfonate as a stabilized pharmaceutical solid preparation, and also to provide a method for preparing the stabilized pharmaceutical solid preparation. The object can be attained by a pharmaceutical solid preparation comprising [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid monobenzenesulfonate which is compound represented by the following formula (I) in combination with (i) one or two or more components selected from the group consisting of D-mannitol, lactose, corn starch, and crystalline cellulose, (ii) carmellose calcium, and (iii) colorants.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: March 31, 2020
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Shinichiro Tajiri, Shinji Yoshinaga, Yurika Ozaki
  • Patent number: 10561697
    Abstract: The present invention is directed to a pharmaceutical, dietary and/or food composition comprising saffron for use in the prevention and/or treatment of degenerative eye disorders. The present invention is also directed to a combination comprising saffron and curcumin, and to a pharmaceutical, dietary and/or food composition comprising said combination for use, by oral route, in the prevention and/or treatment of degenerative eye disorders.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: February 18, 2020
    Assignee: HORTUS NOVUS SRL
    Inventors: Silvia Bisti, Rita Maccarone, Maria Anna Maggi
  • Patent number: 10544153
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids and, for example NSAIDs, chemically conjugated to oxycodone (4,5-?-epoxy-14-hydroxy-17-methylmorphinan-6-one) to form novel prodrugs/compositions of oxycodone, including benzoates, salicylates, propionates, fenamates, and acetates, which have a decreased potential for abuse of oxycodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: January 28, 2020
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera, Bindu Bera, Jaroslaw Kanski, Andrea Martin
  • Patent number: 10525168
    Abstract: A composite comprising: a barrier, said barrier being configured to selectively pass water, and said barrier being degradable in the presence of water; a matrix material for disposition within said barrier, wherein said matrix material has a flowable state and a set state, and wherein said matrix material is degradable in the presence of water; and at least one reinforcing element for disposition within said barrier and integration with said matrix material, wherein said at least one reinforcing element is degradable in the presence of water, and further wherein, upon the degradation of said at least one reinforcing element in the presence of water, provides an agent for modulating the degradation rate of said matrix material in the presence of water.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: January 7, 2020
    Assignee: 206 ORTHO, Inc.
    Inventors: Jeffrey A. D'Agostino, Robert S. Whitehouse, Arthur Watterson, Joseph P. Lane, Ian D. McRury, Samantha Marchetti, Nikole Seil, Werner Blank, Charles Hegedus
  • Patent number: 10485766
    Abstract: Embodiments of the present invention are directed to the oral administration of Bryostatins for the treatment of neuro-degenerative disease.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: November 26, 2019
    Assignees: Aphios Corporation, Board of Supervisors of the Louisiana State University and Agricultural and Mechanical College
    Inventors: Trevor Percival Castor, Jonathan Steven Alexander, Geoffrey Purdum, J. David Rios, Lisa M. Schrott, Theodore A. Tyler, Maria I. Vizcaino
  • Patent number: 10463611
    Abstract: The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound.
    Type: Grant
    Filed: June 7, 2012
    Date of Patent: November 5, 2019
    Assignee: STI PHARMA, LLC
    Inventors: David F. Counts, Donald P. Cox, Anup K. Dam, Michael E. Stalhamer
  • Patent number: 10420728
    Abstract: Disclosed is a method for preparing a tablet. The method can improve the compressibility of the active ingredients and produce tablets of uniform quality, bringing about the advantage of increasing tablet hardness with an increase in compression pressure, easily controlling disintegration time, and decreasing tablet friability by using the active ingredient fimasartan, a pharmaceutically acceptable salt thereof or a hydrate or solvate thereof having a specific particle size distribution.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: September 24, 2019
    Assignee: Boryung Pharmaceutical Co., Ltd.
    Inventors: Jayhyuk Myung, Sung Chan Jeong, Yun Sam Kim
  • Patent number: 10231971
    Abstract: The present invention relates to a composition for preventing or treating dry eye syndrome or eye diseases caused by dry dyes, containing imatinib as an active ingredient and, more specifically, to an eye bath lotion for preventing or treating dry eye syndrome or eye diseases associated with dry eye syndrome, containing imatinib an active ingredient. Imatinib of the present invention effectively protects the corneal epithelia and inhibits the degeneration thereof, thereby being usable for a use of alleviating or treating dry eye syndrome or eye diseases associated with dry eye syndrome.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: March 19, 2019
    Assignee: AVIXGEN INC.
    Inventor: Mi Jeong Kim
  • Patent number: 10196360
    Abstract: Provided are crystal forms I, II, and III of bedaquiline fumarate, and preparation methods thereof. The crystal forms have high purity, excellent physicochemical properties, and good stability. The preparation methods can effectively improve the quality of products, and are applicable to preparation and mass production of medicines.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: February 5, 2019
    Assignee: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Jinyi Xu, Liang Zhang, Xiangyang Zhang, Xinzeng Wang, Jian Chai, Hongying Luo, Zhiqing Yang
  • Patent number: 10172958
    Abstract: An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: January 8, 2019
    Assignee: Tris Pharma, Inc.
    Inventors: Ketan Mehta, Yu-Hsing Tu
  • Patent number: 10086087
    Abstract: A particulate, modified release barrier coated drug-cation exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. Methods of making and products containing this coated complex are described.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: October 2, 2018
    Assignee: Tris Pharma, Inc.
    Inventors: Ketan Mehta, Yu-Hsing Tu
  • Patent number: 10039712
    Abstract: The present invention is drawn to a pharmaceutical composition comprising racecadotril, at least one surfactant and a lipid. The pharmaceutical composition is useful in treating diarrhea.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: August 7, 2018
    Assignee: Johnson & Johnson Consumer Inc.
    Inventor: Der-Yang Lee
  • Patent number: 9974804
    Abstract: A strontium-based composition for controlling progression of osteoarthritis, osteoporosis, and tooth decay is presented. The composition may include a blend of ingredients including: at least 500 mg of strontium carbonate; citric acid; ascorbic acid; malic acid; folic acid; vitamin d3; magnesium citrate; natural sweetener; and flavoring. The all-natural strontium-based blend of ingredients is simply delivered to the oral cavity where an “in-vivo” chemical reaction takes place resulting in direct tooth and dentin exposure to facilitate direct dental anti-caries and anti-sensitivity strontium benefits. The blend of ingredients is then swallowed to establish intestinal transit and absorption to obtain the targeted benefits of systemic absorption to bone and joint areas.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: May 22, 2018
    Inventor: David Lloyd Smith
  • Patent number: 9969701
    Abstract: Novel salts and cocrystals of lesinurad, processes for their preparation, pharmaceutical compositions comprising these new salt forms and co-crystals, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of uric acid transport 1 (URAT1) proteins are disclosed. These novel forms were characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. They can be readily prepared and are suitable for preparation of solid dosage forms owing to their ease of handling and superior pharmacological properties.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: May 15, 2018
    Assignees: Crystal Pharmatech Co., Ltd., Suzhou Pengxu Pharmatech Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Chaohui Yang, Xiaoyu Zhang, Peng Wang, Pixu Li
  • Patent number: 9931358
    Abstract: The present invention provides a tablet core which comprises at least about 95% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 95% by weight of an aliphatic amine polymer resin The method comprises the step of compressing the aliphatic amine polymer to form the tablet core. The tablet core can further include one or more excipients. In this embodiment, the method of producing the tablet core comprises the steps of: (1) hydrating the aliphatic amine polymer to the desired moisture level; (2) blending the aliphatic amine polymer with the excipients in amounts such that the polymer comprises at least about 95% by weight of the resulting blend; and (3) compressing the blend to form the tablet core. The present invention further relates to a coated tablet comprising an aliphatic amine polymer core wherein the coating is a water based coating.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: April 3, 2018
    Assignee: GENZYME CORPORATION
    Inventors: Joseph Tyler, John S. Petersen
  • Patent number: 9913903
    Abstract: Embodiments of the present invention provide methods for the treatment or prevention of infection-related immune conditions using compositions comprising IgM.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: March 13, 2018
    Assignee: Grifols Worldwide Operations Limited
    Inventors: Thomas Barnett, David A. Ross
  • Patent number: 9850252
    Abstract: The presently described technology provides compositions comprising aryl carboxylic acids and, for example NSAIDs, chemically conjugated to oxycodone (4,5-?-epoxy-14-hydroxy-17-methylmorphinan-6-one) to form novel prodrugs/compositions of oxycodone, including benzoates, salicylates, propionates, fenamates, and acetates, which have a decreased potential for abuse of oxycodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: December 26, 2017
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera, Bindu Bera, Jaroslaw Kanski, Andrea Martin
  • Patent number: 9839619
    Abstract: The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 12, 2017
    Assignee: NEOS THERAPEUTICS, LP
    Inventors: Mark Tengler, Russell McMahen
  • Patent number: 9801819
    Abstract: A lipid composition comprising racecadotril, at least one surfactant and a lipid.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: October 31, 2017
    Assignee: Johnson & Johnson Consumer Inc.
    Inventor: Der-Yang Lee
  • Patent number: 9675704
    Abstract: A particulate, pH-independent, modified release barrier coated drug-cation exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. Methods of making and products containing this coated complex are described.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: June 13, 2017
    Assignee: Tris Pharma, Inc.
    Inventors: Ketan Mehta, Yu-Hsing Tu
  • Patent number: 9675703
    Abstract: A particulate, pH-independent, modified release barrier coated drug-cation exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. Methods of making and products containing this coated complex are described.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: June 13, 2017
    Assignee: TRIS PHARMA, INC
    Inventors: Ketan Mehta, Yu-Hsing Tu
  • Patent number: 9636300
    Abstract: A composition comprising racecadotril, at least one surfactant and a lipid.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: May 2, 2017
    Assignee: Johnson & Johnson Consumer Inc.
    Inventor: Der-Yang Lee
  • Patent number: 9566299
    Abstract: The present invention relates to an oral pharmaceutical composition of aliphatic amine polymer or salts thereof comprising mixture of water and organic solvent(s) and/or less than of about 10% of plasticizing agent in the coating composition. In particular, present invention relates to a coated pharmaceutical composition of aliphatic amine polymer or salt thereof which comprises mixture of water and organic solvent(s) and less than of about 10% of plasticizing agent in coating. The invention also includes process of preparing such composition.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: February 14, 2017
    Assignee: WOCKHARDT LIMITED
    Inventors: Girish Kumar Jain, Venkataramana Naidu, Abdul Rehman Khan, Amar Agarwal, Srikanth Pattipati
  • Patent number: 9561204
    Abstract: Effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine and a method of treating acetaminophen poisoning with effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine are described.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: February 7, 2017
    Assignee: ALPEX PHARMA S.A
    Inventors: Federico Stroppolo, Gabriele Granata, Shahbaz S. Ardalan
  • Patent number: 9549941
    Abstract: Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: January 24, 2017
    Assignee: Gilead Pharmasset LLC
    Inventors: Darryl G. Cleary, Charles J. Reynolds, Miriam Michelle Berrey, Robert G. Hindes, William T. Symonds, Adrian S. Ray, Hongmei Mo, Christy M. Hebner, Reza Oliyai, Vahid Zia, Dimitrios Stefanidis, Rowchanak Pakdaman, Melissa Jean Casteel
  • Patent number: 9511019
    Abstract: A stable and/or synergistic pharmaceutical composition including: a) predinisolone metasulfobenzoate (PMSB) or its acceptable salts, preferably prednisolone metasulfobenzoate sodium and b) 5-ASA, derivatives or pharmaceutically acceptable salts thereof, which is suitable for rectal administration.
    Type: Grant
    Filed: August 25, 2010
    Date of Patent: December 6, 2016
    Assignees: NORDIC PHARMA, DISPHAR INTERNATIONAL BV
    Inventors: Hans Schram, Michael Ikechukwu Ugwoke, Laura Buttafoco
  • Patent number: 9511039
    Abstract: The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: December 6, 2016
    Assignee: The Regents of the University of California
    Inventors: Ranjan Dohil, Jerry Schneider
  • Patent number: 9511038
    Abstract: The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: December 6, 2016
    Assignee: The Regents of the University of California
    Inventors: Ranjan Dohil, Jerry Schneider
  • Patent number: 9439866
    Abstract: The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: September 13, 2016
    Assignee: Angelini Pharma, Inc.
    Inventors: Sonia Gervais, Damon Smith, Miloud Rahmouni, Pauline Contamin, Rachid Ouzerourou, My Linh Ma, Angela Ferrada, Fouzia Soulhi
  • Patent number: 9415362
    Abstract: The invention concerns a process for the production of a tableting excipient with the following process steps: At least two of the following components are made available: A filler/binding agent; A lubricant; A flow regulating agent; A disintegrant; The available components are mixed together.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: August 16, 2016
    Assignee: J. Rittenmaier & Sohne GmbH & Co. KG
    Inventors: Edmont Stoyanov, Reinhard Vollmer, Tobias Götz
  • Patent number: 9320716
    Abstract: The invention relates to an oral pharmaceutical composition comprising an active agent, a macroscopically homogeneous structure and a gastro-resistant coating. The macroscopically homogeneous structure comprises at least one hydrophilic compound and at least one lipophilic compound and/or at least one amphiphilic compound. The macroscopically homogeneous structure controls the release of the active ingredient, and the gastro-resistant film prevents release of the active agent in the stomach.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: April 26, 2016
    Assignee: COSMO TECHNOLOGIES LIMITED
    Inventors: Roberto Villa, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati
  • Patent number: 9296686
    Abstract: The present invention relates to the preparation of (R)—N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and (S)—N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide.
    Type: Grant
    Filed: August 25, 2014
    Date of Patent: March 29, 2016
    Assignee: ARDEA BIOSCIENCES, INC.
    Inventors: Andreas Maderna, Jean Michel Vernier
  • Patent number: 9272051
    Abstract: Provided herein are bitter taste receptor ligands, related agents, combinations, compositions, methods and systems for modulating release of a metabolic hormone in vitro or in vivo from cells of the GI tract of an individual.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: March 1, 2016
    Assignees: California Institute of Technology, The Regents of the University of California, The United States Government Represented by the Department of Veterans Affairs
    Inventors: William A. Goddard, III, Mark Menna, Stephen Pandol, Ravinder Abrol